drugset / Trial / NCT00140062

Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.

NCT00140062

Phase 4 Completed 329 enrolled Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.

Timeline

Start
2002-02
Primary completion
Completion
2006-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Latanoprost Small molecule 0.005 %